Innovators publish in JBC on STAT3 inhibition


The innovators, Olov Sterner, Anders Bjartell, Martin Johansson, Eduardo Munoz and with Rebecka Hellsten as head author, have had their latest results accepted for publication in the Journal of Biological Chemistry (JBC). The paper ”Galiellalactone is a direct inhibitor of STAT3 in prostate cancer cells” demonstrates that galiellalactone binds covalently to one or more cysteines in STAT3 thus preventing STAT3 from binding to DNA, leading to inhibition of STAT3 signalling in prostate cancer cells. This peer-reviewed paper further demonstrates that galiellalactone is a promising direct STAT3 inhibitor for treatment of castration-resistant prostate cancer. The paper can be viewed here.